|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer of never smokers exhibited significantly higher ctDNA mutation rates as well as higher EGFR and ERBB2 mutations than ever smokers.
|
28472989 |
2017 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERBB2 was amplified in bladder, breast, colon, stomach, testis, and lung cancer.
|
10473073 |
1999 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
|
12173335 |
2002 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
UNIPROT |
ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.
|
15457249 |
2004 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERBB2 inhibitors, which have so far proved to be ineffective in treating lung cancer, should now be clinically re-evaluated in the specific subset of patients with lung cancer whose tumours carry ERBB2 mutations.
|
15457249 |
2004 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
HER2 mutations are present in a subset of patients with lung cancer having distinct clinical features.
|
21353324 |
2011 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
ERBB2/HER2/NEU, a member of the epidermal growth factor receptor family, is overexpressed in more than 25 % of non-small cell lung cancer and is considered to be a significant and independent prognostic factor in lung cancer.
|
22547270 |
2012 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 and lung cancer.
|
24134423 |
2013 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2-positive lung cancer may not be an adequate term, and patient cohorts for the study of HER2-targeted agents should be defined by the specific HER2 alteration present.
|
26723242 |
2016 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 should be in the clinical genotyping of lung cancer, so patients may benefit from HER2-targeted therapy.
|
27008586 |
2017 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 is a major proliferative driver in lung cancer.
|
28063177 |
2017 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A missense mutation, L755P, in the HER2 kinase domain has been involved in lung cancer in humans and exhibits reduced response to lapatinib therapy.
|
25620423 |
2015 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
|
23612964 |
2013 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activating EGFR mutations, HER2, and HER3 are implicated in lung cancer; however, with the exception of EGFR gene amplification in lung adenocarcinoma harboring EGFR mutations, their involvement in disease progression during the early stages is poorly understood.
|
29473311 |
2018 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
|
30527195 |
2018 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
|
25242668 |
2014 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After MRI diagnosis, breast and lung cancer brain metastases were successfully treated with similar tumor-targeted nanoconjugates carrying molecular inhibitors of EGFR or HER2 instead of imaging contrast agent.
|
25906400 |
2015 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among these, a symmetrical cyclic peptidomimetic (compound 18) exhibited antiproliferative activity in HER2-overexpressing lung cancer cell lines with IC<sub>50</sub> values in the nanomolar concentration range.
|
29436155 |
2018 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An ERBB2 exon 20 insertion-mutated lung cancer cell line had a 50% inhibitory concentration in response to afatinib that was higher than the reported plasma concentration of afatinib, 40 mg daily.
|
26964772 |
2016 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.
|
16609045 |
2006 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
|
20459769 |
2010 |
|
Carcinoma of lung
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Basal ErbB2 phosphorylation was identified in all lung cancer cell lines and was inhibited with an antibody that blocked the NRG-1 binding site on ErbB3.
|
14739033 |
2004 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Because the ErbB receptors play an important role in lung cancer progression, we analyzed the expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, transforming growth factor alpha (TGFalpha), and HER2-neu as potential prognostic factors in stage I NSCLC.
|
14734462 |
2004 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
|
18408761 |
2008 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biologic markers resulting from genetic lesions in lung cancer are grouped as follows: (a) oncogene amplification and overexpression (aberrant gene expression) and mutated tumor suppressor genes -- ras gene, myc gene, HER-2/neu and survivin gene, p53 and mutated beta-tubulin gene; (b) tumor biologic/radiobiologic factors -- tumor cell proliferation kinetics, hypoxia, intrinsic cellular radiosensitivity, gamma factor, and DNA content; (c) enzymes and hormones: neuron-specific enolase, serum lactate dehydrogenase, and enhanced glucose metabolic rate supported by increased glucose transporter protein.
|
11162866 |
2001 |